MUC1 regulation of TGF-beta function in pancreatic cancer cells

MUC1 对胰腺癌细胞中 TGF-β 功能的调节

基本信息

项目摘要

DESCRIPTION (provided by applicant): Pancreatic cancer is a devastating disease with dismal median survival of 3-6 months. The disease is characterized by highly aggressive tumors that are resistant to standard chemo and radiation therapies. MUC1 is a transmembrane mucin glycoprotein that is significantly increased and differentially glycosylated in over 60% of human pancreatic adenocarcinomas (PDA). Further, MUC1 is a marker of aggressive PDA, as its expression is correlated with high metastases, drug resistance, and poor prognosis. However, the underlying mechanisms of MUC1 associated aggressiveness remain unclear. We have new preliminary evidence that PDA cells that do not express MUC1 undergo apoptosis in response to TGF-? whereas PDA cells that express MUC1 undergo EMT and invasion in response to TGF-?. The TGF-?-induced invasion is completely lost when the cytoplasmic tail of MUC1 (MUC1 CT) is mutated. Therefore signal transduction through MUC1 CT is necessary for TGF-?-induced invasion to occur. TGF-? is a major player in carcinogenesis, and is well known for its paradoxical role as both a tumor suppressor and a tumor promoter in pancreatic cancer. Understanding the factors and signals that drive TGF-? function to switch from tumor-suppressor to tumor-promoter is of great interest. We hypothesize that signaling through MUC1-CT supports TGF-?-induced EMT and invasion and inhibits TGF-?-induced apoptosis. The specific aims are: 1) to determine the differential effects of TGF-? induced EMT in MUC1+, MUC1-, and MUC1+ cells in which the tyrosine residues in the MUC1 CT have been mutated to phenylalanine (MUC1 Y0); 2) to determine the differential effects of TGF-? induced apoptosis in MUC1+, MUC1-, and MUC1 Y0 cells. Both in vitro and in vivo experiments are proposed for the aims. If the hypothesis is true, this will be the first demonstration that MUC1 acts as a switch in PDA cells, changing the pro-apoptotic property of TGF-? to an anti-apoptotic and pro-survival property. The knowledge gained will have to be considered when developing future therapies that aim to target the tumor promoting signals of TGF-? while still retaining the pro-apoptotic signals of TGF-?. So far, MUC1 therapeutics has focused on the extracellular region of MUC1 which has not led to clinical success. If the hypothesis holds true, then developing drugs that specifically target MUC1 CT signaling should become a priority.
描述(由申请人提供):胰腺癌是一种毁灭性的疾病,平均生存期为3-6个月。这种疾病的特征是高度侵袭性的肿瘤,对标准化疗和放疗有抵抗力。MUC 1是一种跨膜粘蛋白糖蛋白,在超过60%的人胰腺癌(PDA)中显著增加和差异糖基化。此外,MUC 1是侵袭性PDA的标志物,因为其表达与高转移、耐药性和预后不良相关。然而,MUC 1相关攻击性的潜在机制仍不清楚。我们有新的初步证据表明,PDA细胞,不表达MUC 1进行细胞凋亡的TGF-?而表达MUC 1的PDA细胞在TGF-β诱导下发生EMT和侵袭。TGF-?-当MUC 1的胞质尾区(MUC 1 CT)突变时,诱导的侵袭完全丧失。因此,通过MUC 1 CT的信号转导对于TGF-β-导致入侵发生。TGF-?是癌发生的主要参与者,并且以其在胰腺癌中作为肿瘤抑制剂和肿瘤促进剂的矛盾作用而闻名。了解驱动TGF-β的因素和信号?从肿瘤抑制因子转换为肿瘤促进因子的功能引起了人们极大的兴趣。我们假设通过MUC 1-CT的信号传导支持TGF-β-诱导EMT和侵袭并抑制TGF-β-诱导凋亡。具体目的是:1)确定TGF-?诱导EMT的MUC 1+,MUC 1-,和MUC 1+细胞,其中MUC 1 CT中的酪氨酸残基已突变为苯丙氨酸(MUC 1 Y 0); 2),以确定TGF-?诱导MUC 1+、MUC 1-和MUC 1 Y 0细胞凋亡。为此,提出了体外和体内实验。如果假设是真的,这将是第一次证明MUC 1作为一个开关, PDA细胞,改变促凋亡的TGF-?具有抗细胞凋亡和促生存的特性。所获得的知识将不得不考虑在开发未来的治疗,旨在针对肿瘤促进信号的TGF-?同时仍保留TGF-β的促凋亡信号。到目前为止,MUC 1治疗集中在MUC 1的细胞外区域,这还没有导致临床成功。如果这一假设成立,那么开发专门针对MUC 1 CT信号的药物应该成为优先事项。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
SMAD4-independent activation of TGF-β signaling by MUC1 in a human pancreatic cancer cell line.
  • DOI:
    10.18632/oncotarget.23966
  • 发表时间:
    2018-01-23
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Grover P;Nath S;Nye MD;Zhou R;Ahmad M;Mukherjee P
  • 通讯作者:
    Mukherjee P
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Pinku Mukherjee其他文献

Pinku Mukherjee的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Pinku Mukherjee', 18)}}的其他基金

An integrated strategy using a serum and imaging biomarker for the early detection of pancreatic cancer.
使用血清和成像生物标志物早期检测胰腺癌的综合策略。
  • 批准号:
    10325659
  • 财政年份:
    2021
  • 资助金额:
    $ 7.2万
  • 项目类别:
The use of tMUC1/CD3 bispecific antibody to control pancreatic ductal adenocarcinoma
使用tMUC1/CD3双特异性抗体控制胰腺导管腺癌
  • 批准号:
    10325036
  • 财政年份:
    2021
  • 资助金额:
    $ 7.2万
  • 项目类别:
P-4: Direct Delivery of Immune-modulating Therapies to the Pancreatic Tumor Site
P-4:将免疫调节疗法直接递送至胰腺肿瘤部位
  • 批准号:
    8719563
  • 财政年份:
    2013
  • 资助金额:
    $ 7.2万
  • 项目类别:
MUC1 regulation of TGF-beta function in pancreatic cancer cells
MUC1 对胰腺癌细胞中 TGF-β 功能的调节
  • 批准号:
    8445762
  • 财政年份:
    2013
  • 资助金额:
    $ 7.2万
  • 项目类别:
MUC1 enhances Neuropilin-1 signaling in pancreatic ductal adenocarcinoma
MUC1 增强胰腺导管腺癌中的 Neuropilin-1 信号传导
  • 批准号:
    8434641
  • 财政年份:
    2013
  • 资助金额:
    $ 7.2万
  • 项目类别:
P-4: Direct Delivery of Immune-modulating Therapies to the Pancreatic Tumor Site
P-4:将免疫调节疗法直接递送至胰腺肿瘤部位
  • 批准号:
    7510798
  • 财政年份:
    2008
  • 资助金额:
    $ 7.2万
  • 项目类别:
Role of MUC1 in Pancreatic Cancer
MUC1 在胰腺癌中的作用
  • 批准号:
    7700439
  • 财政年份:
    2006
  • 资助金额:
    $ 7.2万
  • 项目类别:
Role of MUC1 in Pancreatic Cancer
MUC1 在胰腺癌中的作用
  • 批准号:
    7253970
  • 财政年份:
    2006
  • 资助金额:
    $ 7.2万
  • 项目类别:
Role of MUC1 in Pancreatic Cancer
MUC1 在胰腺癌中的作用
  • 批准号:
    7816655
  • 财政年份:
    2006
  • 资助金额:
    $ 7.2万
  • 项目类别:
Role of MUC1 in Pancreatic Cancer
MUC1 在胰腺癌中的作用
  • 批准号:
    7146300
  • 财政年份:
    2006
  • 资助金额:
    $ 7.2万
  • 项目类别:

相似国自然基金

Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 批准年份:
    2020
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 批准年份:
    2016
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 批准年份:
    2014
  • 资助金额:
    73.0 万元
  • 项目类别:
    面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
  • 批准号:
    81301123
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
  • 批准号:
    39500043
  • 批准年份:
    1995
  • 资助金额:
    9.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning
神经元凋亡和修剪过程中凋亡机制的空间限制
  • 批准号:
    10596657
  • 财政年份:
    2021
  • 资助金额:
    $ 7.2万
  • 项目类别:
Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning
神经元凋亡和修剪过程中凋亡机制的空间限制
  • 批准号:
    10417219
  • 财政年份:
    2021
  • 资助金额:
    $ 7.2万
  • 项目类别:
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
  • 批准号:
    441952-2013
  • 财政年份:
    2015
  • 资助金额:
    $ 7.2万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Understanding the activation of pro-apoptotic Bcl-2 family proteins for the development of modulators of apoptosis
了解促凋亡 Bcl-2 家族蛋白的激活以开发凋亡调节剂
  • 批准号:
    nhmrc : 1059331
  • 财政年份:
    2014
  • 资助金额:
    $ 7.2万
  • 项目类别:
    Project Grants
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
  • 批准号:
    441952-2013
  • 财政年份:
    2014
  • 资助金额:
    $ 7.2万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
  • 批准号:
    441952-2013
  • 财政年份:
    2013
  • 资助金额:
    $ 7.2万
  • 项目类别:
    Postgraduate Scholarships - Doctoral
Apoptotic Osteocytes Promote Chondrocyte Apoptosis via Soluble Factors
凋亡骨细胞通过可溶性因子促进软骨细胞凋亡
  • 批准号:
    251802
  • 财政年份:
    2012
  • 资助金额:
    $ 7.2万
  • 项目类别:
    Studentship Programs
Defining the mechanism(s) by which the cellular inhibitor of apoptosis protein 2 (cIAP2) contributes to early stage atherosclerosis development by directly promoting the participation of key apoptotic pathways within lesion-associated macrophages
确定凋亡蛋白细胞抑制剂 2 (cIAP2) 通过直接促进病变相关巨噬细胞内关键凋亡途径的参与来促进早期动脉粥样硬化发展的机制
  • 批准号:
    191299
  • 财政年份:
    2009
  • 资助金额:
    $ 7.2万
  • 项目类别:
    Operating Grants
ATP release during apoptosis and its relevance to apoptotic cell clearance
凋亡过程中 ATP 释放及其与凋亡细胞清除的相关性
  • 批准号:
    8075522
  • 财政年份:
    2009
  • 资助金额:
    $ 7.2万
  • 项目类别:
ATP release during apoptosis and its relevance to apoptotic cell clearance
凋亡过程中 ATP 释放及其与凋亡细胞清除的相关性
  • 批准号:
    7676912
  • 财政年份:
    2009
  • 资助金额:
    $ 7.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了